Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma | MicrobiomeTrials← Back to trialsNCT05025423
Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma
TERMINATEDPHASE2INTERVENTIONAL
Trial Details
Start: 2022-06-21Est. Completion: 2025-05-14
Enrollment target: 7 participants Locations- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Other microbiome trials you might be interested in
Mantle Cell Lymphoma (MCL)Diffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma ( FL)Waldenström Macroglobulinemia (WM)Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
BTK inhibitors and BCL-2 inhibitors have demonstrated significant clinical activity in mature B-cell malignancies, and c…
Multiple LocationsEst. completion Jun 30, 2029
Contiguous Stage II Mantle Cell LymphomaNoncontiguous Stage II Mantle Cell Lymphoma
Stage I Mantle Cell Lymphoma
Stage III Mantle Cell Lymphoma
Stage IV Mantle Cell Lymphoma
This study is being done to see whether or not a drug called ibrutinib can be given to patients with mantle cell lymphom…
Chicago, United StatesCompleted Dec 7, 2021